Joseph Thome
Stock Analyst at TD Cowen
(4.86)
# 365
Out of 4,598 analysts
402
Total ratings
55.1%
Success rate
23.4%
Average return
Main Sectors:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintained: Buy | $90 | $68.12 | +32.13% | 47 | Jul 30, 2026 | |
| QURE uniQure | Maintained: Buy | n/a | $44.06 | - | 27 | Jul 29, 2026 | |
| ALKS Alkermes | Maintained: Buy | $57 → $58 | $49.53 | +17.10% | 21 | Jul 28, 2026 | |
| DYN Dyne Therapeutics | Maintained: Buy | n/a | $25.24 | - | 2 | Jul 28, 2026 | |
| RAPP Rapport Therapeutics | Maintained: Buy | n/a | $40.79 | - | 16 | Jul 17, 2026 | |
| ANAB AnaptysBio | Maintained: Buy | $75 | $53.66 | +39.77% | 24 | Jul 13, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintained: Buy | n/a | $86.01 | - | 7 | Jun 30, 2026 | |
| AXSM Axsome Therapeutics | Rated: Buy | $275 → $300 | $211.04 | +42.15% | 34 | Jun 16, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | n/a | $10.77 | - | 21 | Jun 14, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $275 | $251.58 | +9.31% | 28 | Jun 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.64 | - | 1 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $675 | $516.31 | +30.74% | 29 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $73.78 | - | 8 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.55 | - | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.21 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $23.15 | - | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $62.26 | - | 16 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $125 → $145 | $104.59 | +38.64% | 8 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.26 | - | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.81 | - | 10 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $19.31 | - | 16 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $20.17 | - | 6 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $4.98 | +161.04% | 21 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.03 | - | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.15 | n/a | 9 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 5 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 | $139.86 | n/a | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $11.80 | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $140.78 | n/a | 1 | Oct 1, 2020 |
PTC Therapeutics
Jul 30, 2026
Maintained: Buy
Price Target: $90
Current: $68.12
Upside: +32.13%
uniQure
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $44.06
Upside: -
Alkermes
Jul 28, 2026
Maintained: Buy
Price Target: $57 → $58
Current: $49.53
Upside: +17.10%
Dyne Therapeutics
Jul 28, 2026
Maintained: Buy
Price Target: n/a
Current: $25.24
Upside: -
Rapport Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: n/a
Current: $40.79
Upside: -
AnaptysBio
Jul 13, 2026
Maintained: Buy
Price Target: $75
Current: $53.66
Upside: +39.77%
Arrowhead Pharmaceuticals
Jun 30, 2026
Maintained: Buy
Price Target: n/a
Current: $86.01
Upside: -
Axsome Therapeutics
Jun 16, 2026
Rated: Buy
Price Target: $275 → $300
Current: $211.04
Upside: +42.15%
Intellia Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: n/a
Current: $10.77
Upside: -
Jazz Pharmaceuticals
Jun 12, 2026
Maintained: Buy
Price Target: $275
Current: $251.58
Upside: +9.31%
Jun 11, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $1.64
Upside: -
Jun 5, 2026
Maintained: Buy
Price Target: $675
Current: $516.31
Upside: +30.74%
May 20, 2026
Maintained: Buy
Price Target: n/a
Current: $73.78
Upside: -
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $12.55
Upside: -
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $1.21
Upside: -
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $23.15
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $62.26
Upside: -
May 7, 2026
Rated: Buy
Price Target: $125 → $145
Current: $104.59
Upside: +38.64%
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $7.26
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $2.81
Upside: -
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $19.31
Upside: -
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $20.17
Upside: -
Apr 30, 2026
Maintained: Buy
Price Target: $13
Current: $4.98
Upside: +161.04%
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $5.03
Upside: -
Jul 19, 2024
Rated: Hold
Price Target: n/a
Current: $19.15
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
May 24, 2023
Maintained: Hold
Price Target: $40
Current: $139.86
Upside: n/a
Oct 10, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $11.80
Upside: n/a
Oct 1, 2020
Reiterated: Buy
Price Target: n/a
Current: $140.78
Upside: n/a